---
layout: default
title: Activated Charcoal Antimony Trisulfide Cinchona Of
parent: 僅模型預測 (L5)
nav_order: 191
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Antimony Trisulfide Cinchona Of
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Preparation (Activated Charcoal / Antimony Trisulfide / Cinchona / Gentiana / Ipecac / Leptinotarsa / Silver Nitrate): Repurposing Evaluation Not Feasible

## One-Sentence Summary

This is an unusual seven-component preparation combining botanical, mineral, and entomological ingredients — a profile characteristic of homeopathic or traditional compound formulations. No original approved indication is recorded for this specific combination, no TxGNN repurposing prediction was generated, and the preparation is not marketed in the United States, making a standard drug repurposing evaluation infeasible at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — No prediction available |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This preparation consists of seven structurally unrelated ingredients:

| Component | Known Role |
|-----------|-----------|
| Activated Charcoal | Adsorbent; emergency gastrointestinal decontaminant |
| Antimony Trisulfide | Antimony-based mineral used in traditional/Ayurvedic medicine |
| Cinchona Officinalis Bark | Source of quinine alkaloids; historical antimalarial |
| Gentiana Lutea Root | Bitter tonic; traditional digestive aid |
| Ipecac | Former standard-of-care emetic (largely withdrawn since 2003) |
| Leptinotarsa Decemlineata | Colorado potato beetle; used exclusively in homeopathic preparations |
| Silver Nitrate | Topical antiseptic / astringent; caustic at higher concentrations |

The presence of *Leptinotarsa decemlineata* (Colorado potato beetle) as a named ingredient is a strong marker of a **homeopathic compound preparation**, where ingredients are included at ultra-dilute concentrations based on the principle of similars rather than pharmacological dose-response.

The TxGNN knowledge graph operates on DrugBank-mapped small molecules and their validated targets. Because:
1. No DrugBank ID exists for this combination,
2. Homeopathic ingredients are not represented in the TxGNN knowledge graph, and
3. No original approved indication is available as an anchor for graph traversal,

the model returned zero repurposing candidates. This is an expected and correct result, not a data processing error.

---

## US Market Information

No FDA-approved licenses found for this combination or any of its individual components under this combined submission.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual component risks (for reference only):**
> - **Ipecac syrup** was withdrawn from US market recommendation by the AAP in 2003 due to risk of aspiration, delayed gastric emptying, and misuse in eating disorders — its inclusion in any new formulation would require specific justification.
> - **Silver nitrate** is caustic in concentrated form; systemic absorption can cause argyria.
> - **Antimony compounds** carry known hepatotoxicity and cardiotoxicity risks at pharmacological doses.
> - These concerns apply to pharmacological dosing; homeopathic dilutions are a different regulatory and safety category.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This preparation cannot be evaluated as a drug repurposing candidate under the current framework — there is no DrugBank mapping, no original approved indication, no TxGNN prediction, and no US market presence. The compound profile is consistent with a homeopathic preparation, which operates outside the pharmacological model assumed by TxGNN.

**To proceed, the following is needed:**

- **Clarify regulatory category**: Confirm whether this is a homeopathic OTC product (regulated under DSHEA / OTC Homeopathic Drug Policy) or an investigational compound preparation.
- **Establish individual component mappings**: Each active ingredient should be evaluated independently via DrugBank if pharmacological repurposing is the goal.
- **Obtain original product labeling**: If a marketed product exists under a brand name, locate the package insert to extract approved indications and safety data.
- **Re-run TxGNN per component**: Activated charcoal, cinchona alkaloids (quinine/quinidine), and gentiana iridoids each have documented mechanisms that may yield meaningful predictions when queried individually.
- **Regulatory pathway assessment**: If clinical development is intended, determine whether IND filing under 21 CFR Part 312 is required, or whether the OTC homeopathic monograph pathway applies.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

